Lorlatinib is a Small Molecule owned by Pfizer, and is involved in 41 clinical trials, of which 17 were completed, 23 are ongoing, and 1 is planned.
Lorlatinib is a ATP competitive inhibitor of the receptor tyrosine kinase, anaplastic lymphoma kinase (ALK). Lorlatinib binds to and inhibits ALK kinase. The kinase inhibition leads to disruption of ALK mediated signaling and eventually inhibits tumor cell growth in ALK overexpressing tumor cells. ALK dysregulation and gene rearrangements are associated with a series of tumors.
The revenue for Lorlatinib is expected to reach a total of $8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Lorlatinib NPV Report.
Lorlatinib is originated and owned by Pfizer.
Lorlatinib (Lorviqua / Lorbrena/ Lorlak) is a kinase inhibitor act as anti-neoplastic agent. It is formulated as tablets, coated tablets, film coated tablets for oral route of administration. It is indicated for the treatment of unresectable advanced or recurrent ALK fusion gene positive non-small cell lung cancer unresectable advanced or recurrent fusion gene positive, resistance or intolerance to ALK tyrosine kinase inhibitors, and also for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease, or alectinib as the first ALK inhibitor therapy for metastatic disease, or ceritinib as the first ALK inhibitor therapy for metastatic disease. Lorbrena is indicated as monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC).
Lorlatinib (PF-06463922) is under development for the treatment of metastatic non-small cell lung cancer, anaplastic large cell lymphoma, neuroblastoma . The drug candidate is a new molecular entity (NME). The drug candidate is administered orally as a tablet. It is an ATP competitive small molecule inhibitor of anaplastic lymphoma kinase (ALK). It was under development for the treatment of lymphoma and glioblastoma multiforme.
Pfizer discovers, develops, manufactures and commercializes biopharmaceuticals. The company offers products to treat various conditions such as cardiovascular, metabolic and pain, cancer, inflammation, immune disorders and rare diseases. It also provides sterile injectable pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and contract manufacturing services. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. It has major manufacturing facilities in India, China, Japan, Ireland, Italy, Belgium, Germany, Singapore, and the US. The company provides its products in North America, South America, Asia-Pacific, Australia, Europe, Africa and the Middle East. Pfizer is headquartered in New York, the US.
The company reported revenues of (US Dollars) US$81,288 million for the fiscal year ended December 2021 (FY2021), an increase of 95.2% over FY2020. In FY2021, the company’s operating margin was 29.1%, compared to an operating margin of 18.8% in FY2020. In FY2021, the company recorded a net margin of 27%, compared to a net margin of 22% in FY2020.
Quick View – Lorlatinib
|Highest Development Stage|